Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Apyx Medical CorporationNASDAQ: APYX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $83K rose 232.0% year over year, ahead of the +42.3% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.1% from the prior quarter. Over 3 fiscal years it compounded at +253.4% a year.
Context
- Financing cash flow amounted to 18.1% of revenue in FY2025, up 4.1 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +232.0% holds above the trailing-twelve-month pace of +42.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 9.58M USD
- Year-over-year change
- +42.0%
- 4-year CAGR
- +347.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.58M | +42.0% |
| FY2024 | 2024-12-31 | 6.75M | -79.0% |
| FY2023 | 2023-12-31 | 32.17M | +14723.0% |
| FY2022 | 2022-12-31 | 217K | +804.2% |
| FY2021 | 2021-12-31 | 24K | — |
Financing Cash Flow vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 financing cash flow of $9.64M is the 7th largest of the 8 companies compared; the peer median is $18.76M.
- Its year-over-year change of +42.3% is the 4th highest of 8, against a peer median of +8.7%.
- Financing cash flow amounts to 17.2% of revenue for APYX, versus a peer median of 41.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $49.08M | +8.7% | +182.8% | 955.9% | |
| LTM Mar 2026 | $33.16M | +538.4% | -28.4% | — | |
| LTM Mar 2026 | $21.93M | -319.8% | — | 18.0% | |
| LTM Mar 2026 | $20.67M | +538.0% | +155.1% | 28.6% | |
| LTM Mar 2026 | $18.76M | +4324.8% | +205.6% | 54.6% | |
| LTM Mar 2026 | $11.23M | -1124.4% | -28.2% | 15.0% | |
| LTM Mar 2026 | $9.64M | +42.3% | +253.4% | 17.2% | |
| LTM Mar 2026 | $504K | -99.1% | +2110.8% | 884.2% | |
| Peer median (excluding APYX) | $18.76M | +8.7% | +168.9% | 41.6% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.